1337. SYN-004 (Ribaxamase) Protects the Gut Microbiome of Patients Treated With Ceftriaxone From Disruption and Reduces the Emergence of Antimicrobial Resistance

por Kokai-Kun, John, Le, Charles, Trout, Kenneth, Cope, Julia, Sliman, Joseph
Publicado 2018

Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway

por Muskal, Steven M., Sliman, Joe, Kokai-Kun, John, Pimentel, Mark, Wacher, Vince, Gottlieb, Klaus
Publicado 2016

COVID-19 vaccine platforms: Delivering on a promise?

por Verdecia, Mark, Kokai-Kun, John F., Kibbey, Maura, Acharya, Sarita, Venema, Jaap, Atouf, Fouad
Publicado 2021

SYN-004 (ribaxamase) prevents New Onset Clostridium difficile Infection by Protecting the Integrity Gut Microbiome in a Phase 2b Study

por Kokai-Kun, John, Roberts, Tracey, Coughlin, Olivia, Whalen, Heidi, Le, Charles, Da Costa, Christopher, Sliman, Joseph
Publicado 2017

Ribaxamase, an Orally Administered β-Lactamase, Diminishes Changes to Acquired Antimicrobial Resistance of the Gut Resistome in Patients Treated with Ceftriaxone

por Kokai-Kun, John F, Le, Chenxiong, Trout, Kenneth, Cope, Julia L, Ajami, Nadim J, Degar, Andrew J, Connelly, Sheila
Publicado 2020

The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies

por Kokai-Kun, John F., Roberts, Tracey, Coughlin, Olivia, Sicard, Eric, Rufiange, Marianne, Fedorak, Richard, Carter, Christian, Adams, Marijke H., Longstreth, James, Whalen, Heidi, Sliman, Joseph
Publicado 2017